What is IQV stock price target for 2026?

WallStSmart's 12-month price target for IQVIA Holdings Inc is $166.02, representing 4.8% upside from the current price of $158.37.

What is IQV stock forecast?

IQVIA Holdings Inc forecast includes bull, base, and bear case scenarios from 2026 through 2030. Revenue and EPS projections are derived from analyst consensus and conservative extrapolation with growth deceleration for outer years.

Is IQV undervalued based on price targets?

Our DCF intrinsic value for IQVIA Holdings Inc is $253.57, against a current price of $158.37. The margin of safety is 30.13%.

IQV

IQVIA Holdings Inc

NYSE: IQV · HEALTHCARE · DIAGNOSTICS & RESEARCH

$158.37

+1.09% today

Updated 2026-04-30

Market cap

$26.30B

P/E ratio

20.01

P/S ratio

1.61x

EPS (TTM)

$7.83

Dividend yield

—

52W range

$135 – $247

Volume

1.8M

Market cap

$26.30B

P/E ratio

20.01

P/S ratio

1.61x

EPS (TTM)

$7.83

Dividend yield

—

52W range

$135 – $247

Volume

1.8M

IQVIA Holdings Inc (IQV) Financial Forecast & Price Target 2030

Research-backed projections from analyst consensus, management guidance, and sector analysis.

Price target summary

Current

$158.37

Consensus

$230.56

+45.58%

2030 Target

$1,559.34

+884.62%

DCF

$253.57

+30.13% MoS

Current price

$158.37

Analyst consensus

$230.56

+45.58%

2030 Target

$1,559.34

+884.62%

Intrinsic (DCF)

$253.57

+30.13% MoS

16 analysts:

9 Buy1 Hold0 Sell

Management guidance

IQVIA provided FY2026 guidance of $17.42B revenue (6.77% growth). No specific multi-year targets disclosed through 2030. Company emphasizes AI platform launch (IQVIA.ai with NVIDIA) and strategic acquisitions (Charles River drug discovery assets) as growth drivers.

Sources: Management guidance, analyst consensus, sector analysishigh confidence

Revenue & price projection

Actual revenue Projected revenue Base case Bull to bear range

Bull case (2030)

$2,581.57

$21.9B Rev × 20x P/S

Base case (2030)

$1,559.34

$21.9B Rev × 12x P/S

Bear case (2030)

$1,039.56

$21.9B Rev × 8x P/S

Financial forecast — research-backed

Metric	2023	2024	2025	2026 (E)	2027 (E)	2028 (E)	2029 (E)	2030 (E)
Revenue	$15.0B	$15.4B	$16.3B	$17.4B	$18.4B	$19.5B	$20.7B	$21.9B
Revenue growth	—	2.8%	5.9%	6.8%	5.9%	5.8%	5.9%	6.2%
EPS	$10.21	$9.15	$10.66	$12.82	$14.19	$15.60	$17.10	$18.75
P/S ratio	—	—	—	12.0x	12.0x	12.0x	12.0x	12.0x
Implied price	—	—	—	$1,230.15	$1,299.45	$1,386.08	$1,455.38	$1,559.34

Catalysts & risks

Growth catalysts

+ IQVIA.ai NVIDIA-powered platform adoption by major pharma companies

+ Charles River drug discovery asset integration expanding end-to-end capabilities

+ Real-world evidence demand acceleration in personalized medicine

+ AI-driven operational efficiency gains translating to margin expansion

+ M&A consolidation in CRO industry supporting pricing power

Key risks

- Intense CRO competition and client pricing pressure on margins

- Data privacy regulation and regulatory changes impacting data monetization

- Biotech funding cycles volatility affecting clinical trial demand

- High leverage (Debt/Eq 2.50) limiting financial flexibility

- AI platform adoption execution risk and competitive threats from other vendors

Methodology

IQVIA Holdings Inc's forward estimates are derived from AI-powered research synthesis combining analyst consensus from 16 Wall Street analysts, management guidance from the latest earnings call, and sector growth forecasts from industry research. Revenue and EPS projections use analyst consensus where available and conservative extrapolation with growth deceleration for outer years. Price targets are calculated using a tiered Price-to-Sales (P/S) methodology, where the P/S multiple is determined by the projected revenue growth rate.

WallStSmart proprietary research model · Not financial advice · Past performance is not indicative of future results · Last researched: April 7, 2026.